If a quality specialty pharmaceutical company like Salix Pharmaceuticals (SLXP)
is trading at a discount, you can usually rest assured that it's
because the story has a little too much of what Wall Street hates most -
uncertainty. In the case of Salix, the uncertainty surrounds just why
the FDA rejected its application for subcutaneous form of Relistor and
what, if anything, that means for the oral form of the drug. FDA issues
are no trivial thing for a company like Salix, but nevertheless this
stock looks like a name worth owning.
Please continue here:
Uncertainty Is The Trade-Off For Salix's Appealing Price
No comments:
Post a Comment